Introductory paragraph
Until recently missense germ-line mutations in ACTB, encoding the ubiquitously expressed β-cytoplasmic actin (CYA), were exclusively associated with Baraitser-Winter Cerebrofrontofacial syndrome (BWCFF), a complex developmental disorder 1, 2 . Here, we report six patients with previously undescribed heterozygous variants clustered in the 3'-coding region of ACTB. These patients present with clinical features different from BWCFF, including thrombocytopenia, microcephaly, and mild developmental disability. Patient derived cells are morphologically and functionally distinct from controls. Assessment of cytoskeletal constituents identified a discrete filament population altered in these cells, which comprises force generating and transmitting actin binding proteins (ABP) known to be associated with thrombocytopenia [3] [4] [5] [6] [7] [8] .
In silico modelling and molecular dynamics (MD)-simulations support altered interactions between these ABP and mutant β-
CYA. Our results describe a new clinical syndrome associated with ACTB mutations with a distinct
genotype-phenotype correlation, identify a cytoskeletal protein interaction network crucial for thrombopoiesis, and provide support for the hypomorphic nature of these actinopathy mutations.
Main Text
The human genome encodes six actin isoforms, produced in a time-and tissue-specific manner during development. Isoforms are classified according to their relative isoelectric focusing mobility and enrichment in striated muscle (α-cardiac and α-skeletal actins), smooth muscle (α-smooth and γ-smooth actins (SMA)), and nonmuscle (β-cytoplasmic and γ-cytoplasmic actins (CYA)) tissues 7p22.1 microdeletion in patients with Becker's Nevus Syndrome 13 and a pleotropic developmental disorder 14 .
Through whole-exome or large gene-panel sequencing, we identified 6 patients (P1-6) from 4 unrelated families carrying de novo or co-segregating heterozygous ACTB variants (Table 1,   Supplementary Table 1 ). These mutations cluster in the 3' region of the gene (Fig. 1) , within exons 5 and 6, encoding residues 313-368 of β-CYA ( Supplementary Fig. 1 ). None of these patients showed features associated with BWCFF, for which missense mutations occur within exons 2-4. Transitory or permanent low blood thrombocyte count is common to all patients. Thrombocyte anisotropy is observed in peripheral blood smears and the fraction of immature thrombocytes is elevated (37-45%;
reference range: 1-6%). Bone marrow examination showed an increased megakaryocyte count in P5
( Supplementary Fig. 2 ). Additionally, all mutations are associated with microcephaly. Intellectual function ranges from mild developmental disability to normal intellect. Facial dysmorphism, if observed, appears to be distinct from the typical facial features of BWCFF patients (Table 1 , Supplementary Fig. 3 ). Given the distinct genotype-phenotype correlation, we name this actinopathy
ACTB-associated Thrombocytopenia Microcephaly Syndrome (ACTB-TMS).
Different from ACTB-TMS patients, BWCFF patients have not been reported to display abnormal blood counts 2 . This excludes possible associations with hematological malignancies 15 . One patient with a missense mutation in exon 6 of ACTB displaying moderate intellectual disability and thrombocytopenia, in addition to abnormal white blood cell counts and recurrent infections, was previously reported 16 (Supplementary Table 1 , Patient N). As no cranial measurements were documented by Nunoi et al., we suggest that this patient shares typical ACTB-TMS symptoms. P5, who presented with the most severe clinical symptoms in our cohort, displays partially overlapping white blood cell abnormalities as PN but without leukocytopenia and recurrent infections.
To assess how ACTB-TMS variants affect cytoskeletal organization and cellular function, primary dermal fibroblasts were harvested from P3 and P5. Prominent morphological differences are observed between control and ACTB-TMS fibroblasts (Fig. 2a) . Patient cells cover significantly less substrate surface area than the healthy control ( Fig. 2b) and have ~25% reduced total cell volume ( Fig.   2c) . A distinct feature of P5 fibroblasts is their organization in tightly packed clusters (Fig. 2a, arrow) .
Migration assays show that this occurs as cell-cell interactions cannot be disrupted ( Supplementary   Fig. 4 ). Examination of cell trajectory, migration speed and persistence show that ACTB-TMS cells exhibit limited migratory capacity compared with control cells. No significant differences in cell proliferation rate are observed between the cultures ( Supplementary Fig. 4 ).
Despite differing by only four N-terminal residues, β-CYA and γ-CYA are divergent in their cellular localizations and functions. In the cytoplasm, γ-CYA localizes to sub-membranous networks and promotes cell migration, β-CYA is implicated in contraction and enriches in stress fibers and cellcell contacts [17] [18] [19] . In control and patient fibroblasts, we observe discrete lateral and axial isoactin segregation ( Fig. 3a, Supplementary Fig. 5 ). As previously reported 19 , β-CYA is enriched in subnuclear filaments at the cells' basal plane, whilst γ-CYA is enriched at the cell periphery. These β-CYA sub-nuclear filaments are consistent between healthy control and BWCFF p.Thr120Ile control fibroblasts (P1 in 20 ) , but are phenotypically distinct in ACTB-TMS cells (Fig. 3b) . Here, filaments are bundled into thick fibers and γ-CYA levels are reduced. Despite enrichment of β-CYA at this locality, total protein analysis shows reduced β-CYA levels and a compensatory increase in γ-CYA, whilst total actin is unchanged (Fig. 3c ).
Although typical of vascular smooth muscle tissue, α-SMA is also produced by dermal fibroblasts that undergo myofibroblast differentiation to promote final wound contraction during healing processes 21 . Higher levels of α-SMA are therefore correlated with increased contractile activity, enhanced cell-cell contacts and reduced migratory capacity [22] [23] [24] , consistent with the phenotype of ACTB-TMS fibroblasts. As α-SMA is upregulated in ACTB -/-mouse embryonic fibroblasts 24 , we assessed its expression in ACTB-TMS fibroblasts. Strong signals are observed in both patient cultures by Western blotting ( Supplementary Fig. 5 ). Whilst great variability in α-SMA levels is observed between neighboring cells by immunofluorescence microscopy, the average mean fluorescence intensity (MFI) is significantly increased in P3 and P5 cells compared to healthy and BWCFF controls (Fig. 3d) . α-SMA localizes to basal sub-nuclear filaments in ~80% of ACTB-TMS cells (Fig. 3d.i and iii). Colocalization analysis shows a higher degree of overlap between α-SMA and β-CYA compared to γ-CYA, indicating preferential incorporation of α-SMA into these β-CYA bundles (Fig. 3e , Supplementary Fig. 5 ).
Whole-transcriptome (RNA-Seq) analysis was performed to identify genes, specifically those encoding ABPs, significantly deregulated in P3 and P5 primary fibroblasts compared to healthy control primary fibroblasts (Supplementary Tables 2-4 .
Total protein analysis shows that Diaph1 is unchanged between control and ACTB-TMS samples, whilst all other gene products are increased (Fig. 4b) . By immunofluorescence, we demonstrate enrichment of α-actinin-1 and NM-2A, and the recruitment of filamin A, into basal β-CYA/α-SMA bundles in both P3 and P5 fibroblasts (Fig. 4c ). An antibody recognizing Tpm4.1/4.2 isoforms does not localize to these structures ( Supplementary Fig. 6 ).
Cellular contractile force is generated through ATP-dependent interactions of NM-2 isoforms and filamentous actin 27, 28 . Crosslinkers such as α-actinin stabilize and regulate these interactions, and in combination with the membrane anchoring filamin A, transmit this force to the plasma membrane at focal adhesions, cell-cell junctions, and through interactions with a subset of transmembrane proteins 29, 30 . Studies examining thrombocytopenia-associated mutations of these ABP show that all regulate proplatelet tip formation 3, 7, 8, 31, 32 . Reduced bending and bifurcation of the proplatelet shaft results in the release of fewer, larger thrombocytes, and in the case of NM-2A mutations, immature fractions are elevated 3, 8, [31] [32] [33] [34] [35] . Although proplatelets are not investigated, due to limited patient access, consistencies in thrombocyte properties between our study and these reports suggest proplatelet tip defects are likely in ACTB-TMS megakaryocytes. In support of this, we observe reduced levels and discontinuous staining of β-CYA and NM-2A in P5 ( ). Both mutations perturb the structural integrity of SD1 ( Fig. 5A and Supplementary Notes). The affected SD1 regions are within the interaction interfaces of NM-2 and α-actinin/filamin A ( Fig. 5b and 5c ).
For NM-2, our model suggests significant perturbation for the cardiomyopathy (CM)-loop interaction with β-CYA P3 (Fig. 5b top) . In the case of β-CYA
P5
, modelling and MD-simulations predict significant perturbations for interactions with both the CM-loop and supporting-loop, respectively 37, 38 . For α-actinin/filamin A, hydrophobic interactions are conserved in both β-CYA P3 and β-CYA
, however electrostatic interactions are introduced in β-CYA P3 (Fig. 5c ). Whilst these models support altered interactions between mutant β-CYA and thrombocytopenia-associated ABP, we cannot exclude an effect of N-terminal α-SMA residues on their binding. However, the low level and variable incorporation of α-SMA within sub-nuclear bundles supports that mutant β-CYA is primarily responsible for the altered filament composition observed in ACTB-TMS cells. Further biochemical and structural studies are required to resolve the exact functional consequences of ACTB-TMS mutations at the molecular level.
In conclusion, this work describes a new clinical phenotype associated with mutations clustered in the 3' region of ACTB, named ACTB-TMS. This is the first study to examine the pathogenesis of a human cytoplasmic actinopathy in patient derived cells. For two patients, we study the impact of these hypomorphic mutations at the clinical, cellular and molecular levels (summarized in Supplementary Table 7) . Our results have identified a cytoskeletal phenotype unique to ACTB-TMS, whereby α-SMA is incorporated into mutant β-CYA bundles and a specific subset of ABP is recruited to these filaments. In dermal fibroblasts, these structures are linked with an increased contractile phenotype. We hypothesize that in megakaryocytes, they may limit the incorporation or capacity of essential ABP within proplatelets, compromising proplatelet tip deformation and thrombocyte maturation. Together, these data have resolved key components of a cytoskeletal filament population that both generates and transmits the forces required during the final stages of thrombopoiesis.
Methods

Patient recruitment
This study was approved by the TU Dresden institutional review board (EK127032017) 
Flow cytometry
Patient-derived fibroblasts were cultured in BIO-AMF™-2 Medium in T75 flasks to a confluency of ~70%, washed with 10 ml 1X dPBS and detached using 2 ml Accutase™ (StemCell Technologies, Vancouver, Canada). After 5 minutes incubation at 37°C, the reaction was stopped by adding 2 ml medium. The cells were washed with dPBS containing 0.5% BSA and pelleted by centrifugation. The supernatant was discarded, and cells were fixed by dropwise adding of 1 ml 70% Ethanol cooled to -20°C followed by gentle vortexing. Samples were stored at -20°C until the day of analysis and then pelleted upon adding of 6 ml 4°C dPBS. Two washing steps were carried out with 4 ml and 1 ml 4°C
FACS-buffer (2 mM EDTA and 0,5% BSA in dPBS) and finally cells were resolved in 1 ml 2xUltraPure™ SSC (Invitrogen, Carlsbad, CA, USA). RNA-digestion was performed for 15 minutes at 37°C using 20 µg/ml RNase A (Qiagen) per sample. The samples were washed with 1 ml FACSbuffer and centrifuged for 10 minutes at 4°C and 300 g. For DNA staining, cells were resolved in 300
µl FACS-buffer containing 3 µM Propidium Iodite (Thermo Fisher) and incubated for 30 minutes in the dark at room temperature. All centrifugation steps were carried out at 260 g for 10 minutes if not otherwise mentioned. Samples were analyzed on a LSR Fortessa™ (BD Biosciences) of the Flow Cytometry Core Facility, a core facility of BIOTEC/CRTD at Technische Universität Dresden. Data were manually analysed using FlowJo analysis software (TreeStar, Ashland, OR, USA).
Migration assay
CELLview TM 4 compartment glass bottom dishes (VWR International, Radnor, PA, US) were precoated with fibronectin/gelatin for 1 h at 37°C. Primary fibroblasts were seeded at a density of 2.5 × 10 3 and allowed to attach overnight at 37°C in the presence of 5% CO 2 . Cells received fresh BIO-AMF TM -2 medium supplemented with 10 mM HEPES and dishes were mounted onto an inverted Nikon Eclipse Ti-E microscope system equipped with a 37°C incubator (Nikon). Phase contrast images were acquired at 10 min intervals for 8 h with a 10×/0.30NA objective. For analysis, cells were manually tracked with the MTrackJ plugin in ImageJ. Cells were excluded from the analysis if they collided with another cell or underwent division during the imaging period. The Dicty Tracking 1.4
software package was used to calculate cell trajectories, random migration speeds, directionality ratios and the mean square displacement of cells 44 .
Cell lysis and western blot analysis
Cells grown to 90% confluency in 25 cm 2 Table 8 ). Following two TBS-T washes, membranes were incubated in secondary antibody in blocking solution for 1 h and washed thrice in TBS-T prior to developing. Signals were developed with the SuperSignal TM West Femto Maximum Sensitivity Substrate (Thermo Scientific) and images were obtained with the ChemiDoc MP Imaging system using ImageLab software (Bio-Rad). All antibodies were tested twice with three separate lysates and the levels of β-CYA, γ-CYA, pan-actin and β-tubulin were assessed at least once in all lysates.
Analysis of western blot signals was performed with Image J software (NIH, Bethesda, ML, US).
Values were first adjusted to the total protein content, as determined by Ponceau S staining, and patient samples were normalized to their respective control.
Primary fibroblast immunofluorescence microscopy
For immunofluorescence experiments, cells were seeded at a density of 2 × 10 4 on 10 mm glass coverslips in 24-well plates and cultured for 48 h prior to collection. Cells were washed twice with pre-warmed DMEM/F-12 medium and fixed for 30 min with 1% PFA diluted in DMEM/F-12.
Following two washes with 1× dPBS, cells were permeabilised with ice cold methanol for 5 min. For overlap coefficient analysis, the 'Just Another Colocalization Plugin' was utilized 45 .
Immunofluorescence microscopy of peripheral blood thrombocytes
For control/patient peripheral blood smears, slides were directly fixed in ice cold methanol at 4°C for 5 mins. All subsequent steps were as described above for primary fibroblast immunostaining.
Micrographs with corresponding transmitted light images were collected at a single z-plane with a 60×
Oil/1.35NA objective, 1024×1024 pixel resolution and zoom factor of 3 using the Olympus FluoView 1000 (Olympus, Tokyo, Japan). Fluorescent micrographs were collected with the Leica TCS SP8
Confocal Microscope using a 63× Oil/1.4NA objective, 2048×2048 pixel resolution and 2.5 zoom factor. Z-stack slices had a spacing of 0.3 micron. Maximum intensity projections and fluorescence line profiles were obtained with Image J analysis software (NIH, Bethesda, ML, US).
Whole-transcriptome sequencing (RNA-Seq)
For RNA-Seq, cells were seeded in 75cm 2 flasks and harvested at ~70% confluence. RNA was extracted using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. On column DNA digestion was included to remove residual contaminating genomic DNA. All experiments were done in triplicate. For library preparations, TruSeq Stranded mRNA Library Prep Kit (Illumina) was used according to the manufacturer's protocol, starting with 1 μg total RNA. All barcoded libraries were pooled and sequenced 2x75bp paired-end on an Illumina NextSeq500 platform to obtain a minimum of 10 Mio reads per sample.
Raw reads from Illumina sequencers were converted from bcl to fastq format using bcl2fastq (version v2.17.1.14) allowing for 1 barcode mismatch. Reads were trimmed for quality and sequence adapters using trimmomatic 46 . Trimming resulted in an average of 13.1-22.2Mio reads per sample. All reads were aligned against the phase II reference of the 1000 Genomes Project including decoy sequences d5
(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/phase2_reference_assembly_sequence/hs 37d5.fa.gz) using STAR (v2.5.2b) 47 in a 2-pass mapping mode: first, an index was created using the genome sequence and gene annotation (Gencode GRCh37.p13 comprehensive gene annotation), against which all reads are aligned. Second, all detected splice junctions of all samples are merged and used as guide for the second mapping step. Read counts of all annotated genes were extracted from the alignments using feature Counts method of the Rsubread package (v1.20.6) 48 and genes with 0 counts for all samples were discarded. DESeq2 (v1.10.1) 49 was used to find differentially expressed genes using standard parameters. The differentially expressed genes were filtered using the adjusted p- A subset of 213 genes encoding for known actin binding proteins (based on 56 ) was analyzed further.
As the actin cytoskeleton is abundant in mammalian cells, we rationalized that any proteins substantially influenced by the mutations and in turn influencing patient phenotype, should also be abundantly expressed. As such, genes were eliminated from the analysis when < 300 raw counts were observed in any of the samples analyzed. The remaining 124 ABP genes were sorted based on the log 2 FC values calculated relative to the control. All genes upregulated and downregulated in both patients were then cross-checked on UniProt (http://www.uniprot.org/) and PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) platforms for known associations with thrombocytopenia, as this is the clinical feature most consistent amongst the ACTB-TMS patients.
In silico modeling of β-CYA P3/P5 and ABP interactions
Actin models of β-CYA P3/P5 were built with Yasara (version 17.8.15, YASARA Biosciences GmbH, Germany) based on PDB structure 5JLH 38 . For β-CYA P3 , C-terminal residues after I330 were removed. The frameshift peptide was built via homology modeling using PDB structures as templates. 
Statistical analysis
Unless stated otherwise, GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, US) was utilized for the graphical representation and statistical analysis. For statistical analysis, the Gaussian distribution of data was first assessed. Normally distributed data sets were analyzed with an ordinary one-way ANOVA followed by Holm-Sidak's multiple comparisons test, whilst data that did not follow a Gaussian distribution were treated with the Kruskal-Wallis test followed by Dunn's multiple comparisons test. In both cases, the mean ranks of all three conditions were compared with one another. In all cases, * = P<0.05, ** = P<0.01, *** = P<0.001 and **** = P<0.0001.
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